Entero Healthcare Solutions Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Entero Healthcare Solutions Ltd filed with BSE on 17 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Entero Healthcare reported consolidated revenue growth of 38.2% year-on-year to Rs 1,940 crore for Q1 FY27, with EBITDA margin reaching 5% for the quarter. Management said organic revenue growth was 17.8% on a reported basis, ahead of the underlying pharmaceutical market growth of 13.8%, while inorganic growth came entirely from calendarization of prior-year acquisitions with no new acquisitions completed during the quarter. Management also discussed the composition of margin expansion, non-controlling interest treatment, working capital days, and return ratios for the quarter.
Numbers mentioned
Consolidated revenue growth: 38.2% (Q1 FY27)
p. 3
“Consolidated revenue grew 38.2% year-on-year to INR1,940 crores.”
Prabhat Agrawal, page 3 of the filed PDF · View the filing
Like-for-like revenue growth: 40% (Q1 FY27)
p. 3
“Growth was even stronger at 40% year-on-year.”
Prabhat Agrawal, page 3 of the filed PDF · View the filing
EBITDA margin: 5% (Q1 FY27)
p. 3
“This top line performance was accompanied by continued and meaningful margin improvement with EBITDA margin reaching 5% for the quarter.”
Prabhat Agrawal, page 3 of the filed PDF · View the filing
Organic revenue growth: 17.8% (Q1 FY27)
p. 3
“Organic revenue growth for the quarter was 17.8% on a reported basis and 19.6% on a like-for-like basis, comfortably ahead of the underlying pharmaceutical market growth of 13.8%.”
Prabhat Agrawal, page 3 of the filed PDF · View the filing
Inorganic growth: 20.4% (Q1 FY27)
p. 3
“Inorganic growth was at 20.4% and the entirety of this growth came from the calendarization of acquisitions completed in last year.”
Prabhat Agrawal, page 3 of the filed PDF · View the filing
Gross margin: 11.4% (Q1 FY27)
p. 4
“Gross margin expanded 147 basis points year-on-year to 11.4% and EBITDA margin expanded 143 basis points to 5%, while EBITDA growing 94% year-on-year, nearly 2.5x our revenue growth rate.”
Prabhat Agrawal, page 4 of the filed PDF · View the filing
Profit after tax: INR52 crores (Q1 FY27)
p. 4
“Profit after tax for the quarter was INR52 crores, up 72% year-on-year with a PAT margin of 2.7%.”
Prabhat Agrawal, page 4 of the filed PDF · View the filing
Profit after tax attributable to owners: INR38 crores (Q1 FY27)
p. 4
“Profit after tax attributable to owners was INR38 crores, up 37% year-on-year.”
Prabhat Agrawal, page 4 of the filed PDF · View the filing
Non-controlling interest: INR14 crores (Q1 FY27)
p. 4
“I would like to provide some clarification in reference to the non-controlling interest, which stood at INR14 crores for the quarter or approximately 27% of profit before minority interest.”
Prabhat Agrawal, page 4 of the filed PDF · View the filing
Net working capital days: 61 days (Q1 FY27)
p. 4
“Net working capital days improved to 61 days from 66 days a year ago, continuing the structural efficiency gains from the initiatives we have been taking since the past few quarters.”
Prabhat Agrawal, page 4 of the filed PDF · View the filing
ROCE: 21.1% (Q1 FY27)
p. 4
“ROCE yearly doubled year-on-year from 11.5% to 21.1% and ROE moved from 9% to 20.4%.”
Prabhat Agrawal, page 4 of the filed PDF · View the filing
Retail customers served: over 72,000 (Q1 FY27)
p. 5
“We now serve over 72,000 retail customers and more than 2,300 hospital customers, distribute over 83,400 SKUs and maintain relationships with more than 3,000 health care product manufacturers, supported by 138 warehouses across 475 districts in 19 states.”
Prabhat Agrawal, page 5 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Consolidated revenue growth — approximately 23% year-on-year, excluding new acquisitions · FY27
stated firmly by Prabhat Agrawal
p. 5
“We remain firmly committed to our stated FY27 guidance of consolidated revenue growth of approximately 23% year-on-year, excluding any contribution from new acquisitions, alongside an EBITDA margin of 5% and EBITDA to operating cash flow conversion of 50%.”
Prabhat Agrawal, page 5 of the filed PDF · View the filing
MedTech revenue — cross INR1,000 crores · FY27
stated firmly by Prabhat Agrawal
p. 16
“Yes, yes. We are comfortably above those above INR1,000 crores for this full year.”
Prabhat Agrawal, page 16 of the filed PDF · View the filing
Business growth rate (organic + inorganic combined) — in excess of 20% · next 3 to 4 years
stated as an aspiration by Prabhat Agrawal
p. 6
“So, coming back to your question, in near term, we believe that we should be able to grow at excess of 20%.”
Prabhat Agrawal, page 6 of the filed PDF · View the filing
ROCE — 25% to 30% · end of third or fourth year
stated as an aspiration by Prabhat Agrawal
p. 6
“Anywhere, in the range of 25% to 30%.”
Prabhat Agrawal, page 6 of the filed PDF · View the filing
MedTech growth — 20% · 3 to 5-year period
stated as an aspiration by Prabhat Agrawal
p. 14
“20%, we can definitely target those kinds of growth rates in MedTech.”
Prabhat Agrawal, page 14 of the filed PDF · View the filing
EBITDA margin — more than 6%
stated as an aspiration by Prabhat Agrawal
p. 16
“Yes. Yes. We have internal aspiration and target would be more than 6% for sure.”
Prabhat Agrawal, page 16 of the filed PDF · View the filing
Employee expenses — rest of FY27
stated firmly by Prabhat Agrawal
p. 8
“So you should not expect any major increase on employee expenses from here on.”
Prabhat Agrawal, page 8 of the filed PDF · View the filing
Interest costs — rest of FY27
stated firmly by Balakrishnan Kaushik
p. 9
“This will be broadly in the same range. We don't expect it to significantly go down, but it will be broadly in the same range.”
Balakrishnan Kaushik, page 9 of the filed PDF · View the filing
Working capital days guidance — FY27
stated firmly by Prabhat Agrawal
p. 10
“No, we will stay with our guidance. I'm not revising any guidance numbers based on quarter 1 performance.”
Prabhat Agrawal, page 10 of the filed PDF · View the filing
Minority interest buyout timeline — 2 to 5 years · per acquisition agreement
stated firmly by Prabhat Agrawal
p. 8
“It could be anywhere between 2 to 5 years.”
Prabhat Agrawal, page 8 of the filed PDF · View the filing
Income tax rate — 22.5% · FY27
stated firmly by Balakrishnan Kaushik
p. 11
“The guidance for FY27, we've given a 22.5%.”
Balakrishnan Kaushik, page 11 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said Entero can grow in excess of 20% organically and inorganically combined over the near term of 3-4 years, even assuming no acquisitions.
Answered by Prabhat Agrawal
Asked by Bharat C Shah: If no more acquisitions are made and IPM grows 7-9%, what growth rate can Entero achieve over 3-5 years?
p. 6
“So, coming back to your question, in near term, we believe that we should be able to grow at excess of 20%.”
Prabhat Agrawal, page 6 of the filed PDF · View the filing
Most subsidiaries were funded through intercompany loans, which are pulled back once they generate cash, giving the parent company funds to acquire more businesses.
Answered by Prabhat Agrawal
Asked by Arnav Sakhuja: How is cash flow from subsidiaries brought back to the parent to fund acquisitions?
p. 7
“So most of the subsidiaries have been funded through inter-company deposits or intercompany loans. So, once we start making money, we pull back those intercompany loans that gives us cash flow in the parent company to acquire more businesses.”
Prabhat Agrawal, page 7 of the filed PDF · View the filing
Management said removing one-off items from Q4 shows margins were already close to 5%, and the aspiration is to improve further.
Answered by Prabhat Agrawal
Asked by Akshat Mehta: What drove the sequential margin improvement from Q4 to Q1 and can margins improve further?
p. 8
“So, quarter 4 to quarter 1 anyway, we were close to 5%. And because we -- if you remember, we had given a clarification also that there were certain one-off items in quarter 4, that kind of brought down our margins.”
Prabhat Agrawal, page 8 of the filed PDF · View the filing
Management attributed it to a preponement of government project billing into Q4 of the prior year due to budget closing, creating a high base.
Answered by Prabhat Agrawal
Asked by Chetan: What explains the drop in inorganic contribution to revenue growth versus last quarter?
p. 9
“No, that's the main reason. In the last call also, I said there were certain government projects that we're doing. And there were a preponement of billing in last quarter itself because of the government budget is getting closed down.”
Prabhat Agrawal, page 9 of the filed PDF · View the filing
Management said they cannot isolate a specific reason for the IPM growth uptick and cannot forecast whether it will sustain, though they remain confident in their own growth projections.
Answered by Prabhat Agrawal
Asked by Alok Dalal: Is the recent improvement in IPM growth sustainable and what is driving it?
p. 10
“So, we are not able to decipher the exact reason of why there is a meaningful change in the growth rate, even though we are experiencing that growth, but we are not able to isolate any specific reason or factor for that.”
Prabhat Agrawal, page 10 of the filed PDF · View the filing
Management clarified that OCF is EBITDA after working capital changes, and the resulting cash can be used for acquisitions, debt repayment, or buying out minorities, whichever creates the most EPS improvement.
Answered by Prabhat Agrawal
Asked by Kumar Saurabh: With margin improvement, can the company fund incremental working capital internally without needing more debt?
p. 12
“Now we are saying that in this year, we will have 50% left after accounting for working capital changes, is that money could be used for acquisition, could be used for paying off debt, it can be used for buying of minorities.”
Prabhat Agrawal, page 12 of the filed PDF · View the filing
Management said they target higher margins quarter-on-quarter but maintain the 5% full-year guidance for now, with a possible update after H1 performance.
Answered by Prabhat Agrawal
Asked by Rashmi Gohil: Is 5% EBITDA margin a floor for FY27 or should further sequential expansion be expected?
p. 17
“So, we are always targeting higher margins quarter-on-quarter. But for the full year guidance basis, we still maintain 5%, as I told before that after quarter 2, I might come out with a different number.”
Prabhat Agrawal, page 17 of the filed PDF · View the filing
Management said balance sheet figures are only reviewed/audited twice a year (September and March) and those numbers would be disclosed then.
Answered by Prabhat Agrawal
Asked by Binoy Jariwala: Can management share gross debt, net debt and OCF numbers for the quarter?
p. 15
“So, we are not getting our balance sheet reviewed or balance sheet audited by auditors in quarter-to-quarter basis. It's done twice in a year, which is in September and March.”
Prabhat Agrawal, page 15 of the filed PDF · View the filing
Risks flagged
Inability to forecast or explain the recent acceleration in IPM industry growth rate
p. 10
“So, we are not able to decipher the exact reason of why there is a meaningful change in the growth rate, even though we are experiencing that growth, but we are not able to isolate any specific reason or factor for that.”
Prabhat Agrawal, page 10 of the filed PDF · View the filing
Seasonality in the pharma business affecting quarterly OCF and inventory needs
p. 16
“The reason being there is some bit of seasonality in pharma business. There is Q2 is typically higher business for entire industry as a whole.”
Prabhat Agrawal, page 16 of the filed PDF · View the filing
Historical cyclicality of IPM growth rate fluctuating between 7% and 14%
p. 13
“We were in that cycle of 10% to 12%, then we went down to 7% to 9%.”
Prabhat Agrawal, page 13 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.